Company profile: Assertio
1.1 - Company Overview
Company description
- Provider of pharmaceutical therapies for pain and inflammation and oncology support, offering Cambia (diclofenac potassium) for acute pain; INDOCIN oral suspension and suppositories (indomethacin); SPRIX nasal spray (ketorolac) for short-term moderate to severe pain; Otrexup (methotrexate) injection for certain cancers and autoimmune diseases; and ROLVEDON to reduce severe neutropenia in chemotherapy patients.
Products and services
- SPRIX (ketorolac tromethamine) Nasal Spray: Nasal spray-formulated ketorolac tromethamine for short-term management of moderate to severe pain via nasal administration
- Cambia (diclofenac potassium) Oral Solution: Oral solution-formulated medication that treats acute pain and inflammation, using diclofenac potassium for oral solution administration
- INDOCIN Oral Suspension: Liquid suspension-formulated indomethacin that addresses pain and inflammation via oral administration as a fluid dosage form
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Assertio
CoLucid
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting central nervous system disorders, developing COL-144, a neurally acting anti-migraine agent for treating migraine, and COL-204, a conjugated stigmine platform producing novel chemical entities for therapy of sleep/wake disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoLucid company profile →
NeuroCycle Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on sub-type selective GABA-A modulation, including a lead candidate (NCT10004) that selectively targets a newly identified mechanism of action to reduce itch to near-baseline levels across models, including allergic and contact dermatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroCycle Therapeutics company profile →
OrthoCor Medical
HQ: United States
Website
- Description: Provider of drug-free, noninvasive, mobile medical devices for joint pain, including wearable PEMF therapy systems for major joints; a knee device with motion sensing and a smart app for enhanced pain management and recovery tracking; and single-use OrthoPods that activate PEMF sessions, providing heat and therapeutic benefits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrthoCor Medical company profile →
Saluda Medical
HQ: United States
Website
- Description: Provider of smart spinal cord stimulation solutions for chronic pain, featuring the Evoke System that measures ECAPs and auto-adjusts therapy via SmartLoop Technology. Offers ECAP-based precise therapy adjustment, FDA-approved MRI compatibility under specific conditions, conducts clinical trials to validate safety and efficacy, and benefits from CMS transitional pass-through payment to expand patient access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Saluda Medical company profile →
NanoVibronix
HQ: United States
Website
- Description: Provider of portable therapeutic ultrasound medical devices, including PainShield, a wearable device delivering localized energy to relieve pain and promote soft tissue healing; UroShield, a urology device that creates an acoustic shield on urinary catheters to prevent bacterial biofilm, reduce infections, and alleviate catheter-related pain and discomfort; and WoundShield, a patch-based device that promotes wound healing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoVibronix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Assertio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Assertio
2.2 - Growth funds investing in similar companies to Assertio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Assertio
4.2 - Public trading comparable groups for Assertio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →